GamaMabs Pharma SA

13 articles about GamaMabs Pharma SA

• Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target

  5/4/2021

  - Early clinical data of naked monoclonal antibodies support safety of targeting anti-Müllerian hormone receptor 2 (AMHR2), an oncology target of interest - - Antibody-drug conjugates (ADCs) targeting AMHR2 could provide clinical efficacy in gynecologic, colorectal and other forms of cancer -

• GamaMabs Pharma announces presentation of murlentamab phase 2 study results in colorectal cancer at ESMO World Congress on Gastrointestinal Cancer

  7/5/2019

  Longer than expected PFS for murlentamab when combined with FTD/TPI, particularly in patients with medium/high AMHRII expression, along with immune cascade activation in the tumor micro-environment

• GamaMabs Pharma to present updated results at 2019 ASCO Annual Meeting from the First-In-Human clinical study of murlentamab in advanced gynecological cancers

  5/22/2019

  Objective responses, good safety and evidence of stimulation of the immune system observed under murlentamab (GM102) single agent and in combination with chemotherapy

•  GamaMabs Pharma starts a phase 2 study of monoclonal antibody GM102 in patients with advanced or metastatic colorectal cancer 

  9/17/2018

  C201 phase 2 will study immuno-enhancer antibody GM102, targeting AMHRII as a single agent and in combination with Trifluridine/Tipiracil (Lonsurf®) 

• GamaMabs Pharma to present at 2018 ASCO Annual Meeting results from the First-In-Human clinical study of GM102 in advanced gynecological cancers

  5/23/2018

  GamaMabs Pharma announces the upcoming presentation of clinical data from the First-In-Human C101 phase Ia/Ib study of its GM102 antibody during the American Society of Clinical Oncology (ASCO) Annual Meeting, on June 4 in Chicago, USA.

• GamaMabs Pharma Receives Orphan Drug Designation From US FDA for Lead Compound GM102

  2/7/2018

  GM102 is a first-in-class monoclonal antibody targeting AMHR2-expressing tumors.

• GamaMabs Pharma Sees Two Peer-Reviewed Articles Published in Oncotarget, Detailing the Anti-Tumor Activity of GM102/3C23K

  12/4/2017

  The studies were performed by GamaMabs' partners, including the Institut de Recherche en Cancerologie de Montpellier, Inserm, Institut Curie and the Institut Gustave Roussy.

• GamaMabs Pharma SA And MedImmune Enter Licensing Agreement To Develop Antibody Drug Conjugate Targeting Cancer

  10/10/2017

• GamaMabs Pharma SA Starts Phase Ia/Ib Study Of First-In-Class Monoclonal Antibody GM102 In Advanced Gynecological Cancer

  7/26/2016

• GamaMabs Pharma SA Strengthens Its Governance With The Appointment Of Martine J George, M.D., As Independent Board Member

  5/3/2016

• GamaMabs Pharma SA Raises €15 Million In Series B Financing Round

  12/16/2015

• Curie-Cancer And GamaMabs Pharma SA Renew Their Research Partnership To Develop An Antibody For Gynecological Cancers

  12/17/2014

• GamaMabs Pharma SA Announces Two Scientific Communications On Its AMHR2 Project

  9/4/2014